利妥昔单抗治疗恶性淋巴瘤的进展

利妥昔单抗（人源化CD20单克隆抗体，商品名美罗华）是首个批准用于治疗表达CD20恶性淋巴省的单克隆抗体，广泛应用于低度恶性非雷奇金琳巴瘤（NHL）、侵袭性NHL，亦试用于霍奇金淋巴瘤（HL）及其他B细胞性恶性肿瘤。刊蚤昔单抗联合细胞毒性药物的疗效已在B细胞NHL的有关临床试验中得到证实。目前该药已被批准用于侵袭性淋巴瘤和惰性淋巴瘤的一线治疗，其维持治疗滤泡性淋巴瘤亦得出鼓舞人心的结果．利妥昔单抗已成为治疗B细胞性恶性淋巴瘤的重要手段之一。

Advances of rituximab in the treatment of malignant lymphoma

The chimeric anti-CD20 monoclonal antibody rituximab is the first humanized monoclonal antibody approved for patients with malignant lymphoma with CD20 expression. Rituximab has been approved to treat indolent non-Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma as first-line medication. Other indications of this agent used to manage Hodgkin's lymphoma and other B-cell malignancies were in the clinical trial stage. The adjunctive therapy of rituximab with cytotoxic agents or cyto-kines has been impressed in many clinical studies. The maintenance treatment of indolent non-Hodgkin's lymphoma with rituximab also yielded promising results. Rituximab has become the part of standard therapy for B cell non-Hodgkin's lymphoma.